U.S. P2Y12 Inhibitors Market
- 2026 年市場規模
- USD 23.7 Bn
- 2033 年預估規模
- USD 38.3 Bn
- 年複合成長率 CAGR
- 8.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
U.S. P2Y12 Inhibitors Market, By Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), By Route of Administration (Oral and 52), By Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
報告摘要
P2Y12 receptor blockers are group of antiplatelet drugs. Antiplatelet are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. A blood clot can lead to a heart attack or stroke. The P2Y12 receptor is a key player in platelet activation and represents an effective pharmacological target for the inhibition of platelet aggregation and prevention of atherothrombotic events. P2Y12 receptor blocker includes clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor drugs
Market Dynamics
Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019 by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.
Key features of the study
• This report provides in-depth analysis of the U.S. P2Y12 inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. P2Y12 inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. P2Y12 inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. P2Y12 inhibitors market
Market Segmentation
• By Drug
o Clopidogrel
o Ticlopidine
o Ticagrelor
o Prasugrel
o Cangrelor
o Others
• By Route of Administration
o Oral
o Intravenous
• By Application
o Angioplasty
o Arterial Thrombosis
o Percutaneous Coronary Interventions
o Myocardial Infarction
o Others
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Key Players Insights
o Mylan N.V.
o Bristol-Myers Squibb
o Dr Reddy's Laboratories
o Teva Pharmaceuticals USA, Inc.
o AstraZeneca
o Genentech
o Eli Lilly and Company
o Panacea Biotec
o CHIESI USA, Inc.
o Lupin
o Cipla
o Biocon
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Route of Administration
Market Snapshot, By Application
Market Snapshot, By Distribution Channel
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Pipeline Analysis
o Regulatory Scenario
o PEST Analysis
o Epidemiology
o Product Launch/Approvals
o Acquisition, Collaboration & Agreements
o Key Developments
o Therapeutic Landscape
4. U.S. P2Y12 Inhibitors Market, By Drug, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Clopidogrel
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Ticlopidine
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Ticagrelor
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Prasugrel
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Cangrelor
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. U.S. P2Y12 Inhibitors Market, By Route of Administration, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Oral
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Intravenous
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. U.S. P2Y12 Inhibitors Market, By Application, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Angioplasty
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Arterial Thrombosis
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Percutaneous Coronary Interventions
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Myocardial Infarction
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. U.S. P2Y12 Inhibitors Market, By Distribution Channel, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Hospital Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Retail Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Online Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Mylan N.V.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Bristol-Myers Squibb
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Dr Reddy's Laboratories
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Teva Pharmaceuticals USA, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
AstraZeneca
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Genentech
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Panacea Biotec
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
CHIESI USA, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Lupin
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Cipla
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
Biocon
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Overview
o Strategy
o Analyst Views
9. Section
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們